메뉴 건너뛰기




Volumn 20, Issue 9, 2014, Pages 2363-2374

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CD135 ANTIGEN; COMPLEMENTARY DNA; CP 868 596; CRENOLANIB; MIDOSTAURIN; QUIZARTINIB; SORAFENIB; TANDUTINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

EID: 84899758381     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2052     Document Type: Article
Times cited : (45)

References (43)
  • 1
    • 0030451722 scopus 로고    scopus 로고
    • Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
    • Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-8.
    • (1996) Leukemia , vol.10 , pp. 1911-1918
    • Nakao, M.1    Yokota, S.2    Iwai, T.3    Kaneko, H.4    Horiike, S.5    Kashima, K.6
  • 2
    • 0035871889 scopus 로고    scopus 로고
    • Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
    • Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9.
    • (2001) Blood , vol.97 , pp. 2434-2439
    • Yamamoto, Y.1    Kiyoi, H.2    Nakano, Y.3    Suzuki, R.4    Kodera, Y.5    Miyawaki, S.6
  • 3
    • 0036720398 scopus 로고    scopus 로고
    • The roles of FLT3 in hematopoiesis and leukemia
    • Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
    • (2002) Blood , vol.100 , pp. 1532-1542
    • Gilliland, D.G.1    Griffin, J.D.2
  • 4
    • 78649340278 scopus 로고    scopus 로고
    • Activation state-dependent binding of small molecule kinase inhibitors: Structural insights from biochemistry
    • Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, et al. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.ChemBiol 2010;17:1241-9.
    • (2010) ChemBiol , vol.17 , pp. 1241-1249
    • Wodicka, L.M.1    Ciceri, P.2    Davis, M.I.3    Hunt, J.P.4    Floyd, M.5    Salerno, S.6
  • 5
    • 57749188299 scopus 로고    scopus 로고
    • Targeting cancer with small molecule kinase inhibitors
    • Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
    • (2009) Nat Rev Cancer , vol.9 , pp. 28-39
    • Zhang, J.1    Yang, P.L.2    Gray, N.S.3
  • 6
    • 0033026444 scopus 로고    scopus 로고
    • Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
    • Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:195-206.
    • (1999) Pharmacol Ther , vol.82 , pp. 195-206
    • Traxler, P.1    Furet, P.2
  • 7
    • 58149102648 scopus 로고    scopus 로고
    • Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states
    • Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. JMed Chem 2008;51:7921-32.
    • (2008) JMed Chem , vol.51 , pp. 7921-7932
    • Kufareva, I.1    Abagyan, R.2
  • 8
    • 33745298429 scopus 로고    scopus 로고
    • Rational design of inhibitors that bind to inactive kinase conformations
    • Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64.
    • (2006) Nat Chem Biol , vol.2 , pp. 358-364
    • Liu, Y.1    Gray, N.S.2
  • 11
    • 77951645227 scopus 로고    scopus 로고
    • Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
    • Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-62.
    • (2010) J Clin Oncol , vol.28 , pp. 1856-1862
    • Ravandi, F.1    Cortes, J.E.2    Jones, D.3    Faderl, S.4    Garcia-Manero, G.5    Konopleva, M.Y.6
  • 12
    • 80054771760 scopus 로고    scopus 로고
    • Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantationwith sorafenib
    • Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantationwith sorafenib. Biol Blood Marrow Transplant 2011;17:1874-7.
    • (2011) Biol Blood Marrow Transplant , vol.17 , pp. 1874-1877
    • Sharma, M.1    Ravandi, F.2    Bayraktar, U.D.3    Chiattone, A.4    Bashir, Q.5    Giralt, S.6
  • 13
    • 84860747223 scopus 로고    scopus 로고
    • Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
    • Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012;485:260-3.
    • (2012) Nature , vol.485 , pp. 260-263
    • Smith, C.C.1    Wang, Q.2    Chin, C.S.3    Salerno, S.4    Damon, L.E.5    Levis, M.J.6
  • 14
    • 33845240584 scopus 로고    scopus 로고
    • Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or highrisk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics
    • DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or highrisk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006;108:3674-81.
    • (2006) Blood , vol.108 , pp. 3674-3681
    • Deangelo, D.J.1    Stone, R.M.2    Heaney, M.L.3    Nimer, S.D.4    Paquette, R.L.5    Klisovic, R.B.6
  • 15
    • 84875632298 scopus 로고    scopus 로고
    • Acute myeloid leukemia: 2013 update on risk-stratification and management
    • Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013;88:318-27.
    • (2013) Am J Hematol , vol.88 , pp. 318-327
    • Estey, E.H.1
  • 16
    • 33751173636 scopus 로고    scopus 로고
    • A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as firstline treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
    • Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as firstline treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-70.
    • (2006) Blood , vol.108 , pp. 3262-3270
    • Knapper, S.1    Burnett, A.K.2    Littlewood, T.3    Kell, W.J.4    Agrawal, S.5    Chopra, R.6
  • 17
    • 19944427559 scopus 로고    scopus 로고
    • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
    • Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
    • (2005) Blood , vol.105 , pp. 54-60
    • Stone, R.M.1    Deangelo, D.J.2    Klimek, V.3    Galinsky, I.4    Estey, E.5    Nimer, S.D.6
  • 18
    • 70449475105 scopus 로고    scopus 로고
    • AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    • Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114: 2984-92.
    • (2009) Blood , vol.114 , pp. 2984-2992
    • Zarrinkar, P.P.1    Gunawardane, R.N.2    Cramer, M.D.3    Gardner, M.F.4    Brigham, D.5    Belli, B.6
  • 19
    • 80052231301 scopus 로고    scopus 로고
    • FLT3 inhibition as therapy in acute myeloid leukemia: A recordof trials andtribulations
    • Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a recordof trials andtribulations.Oncologist 2011;16:1162-74.
    • (2011) Oncologist , vol.16 , pp. 1162-1174
    • Fathi, A.T.1    Chabner, B.A.2
  • 20
    • 30144432781 scopus 로고    scopus 로고
    • Clinical resistance to the kinase inhibitor PKC412 in acutemyeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
    • Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, et al.Clinical resistance to the kinase inhibitor PKC412 in acutemyeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006;107:293-300.
    • (2006) Blood , vol.107 , pp. 293-300
    • Heidel, F.1    Solem, F.K.2    Breitenbuecher, F.3    Lipka, D.B.4    Kasper, S.5    Thiede, M.H.6
  • 21
    • 66149152278 scopus 로고    scopus 로고
    • FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro
    • von BN, Engh RA, Aberg E, Sanger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009;69:3032-41.
    • (2009) Cancer Res , vol.69 , pp. 3032-3041
    • Von, B.N.1    Engh, R.A.2    Aberg, E.3    Sanger, J.4    Peschel, C.5    Duyster, J.6
  • 22
    • 84873567125 scopus 로고    scopus 로고
    • Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
    • Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013;27:48-55.
    • (2013) Leukemia , vol.27 , pp. 48-55
    • Williams, A.B.1    Nguyen, B.2    Li, L.3    Brown, P.4    Levis, M.5    Leahy, D.6
  • 23
    • 84863785488 scopus 로고    scopus 로고
    • Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns
    • Moore AS, Faisal A, de Castro DG, Bavetsias V, Sun C, Atrash B, et al. Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 2012;26:1462-70.
    • (2012) Leukemia , vol.26 , pp. 1462-1470
    • Moore, A.S.1    Faisal, A.2    De Castro, D.G.3    Bavetsias, V.4    Sun, C.5    Atrash, B.6
  • 24
    • 79955942168 scopus 로고    scopus 로고
    • Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations
    • Scholl S, Spies-Weisshart B, Klink A, Muegge LO, Fricke HJ, Hochhaus A. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Ann Hematol 2011;90:473-5.
    • (2011) Ann Hematol , vol.90 , pp. 473-475
    • Scholl, S.1    Spies-Weisshart, B.2    Klink, A.3    Muegge, L.O.4    Fricke, H.J.5    Hochhaus, A.6
  • 25
    • 0036799356 scopus 로고    scopus 로고
    • Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
    • Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002;16:2027-36.
    • (2002) Leukemia , vol.16 , pp. 2027-2036
    • Tse, K.F.1    Allebach, J.2    Levis, M.3    Smith, B.D.4    Bohmer, F.D.5    Small, D.6
  • 26
    • 84881035623 scopus 로고    scopus 로고
    • Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT3 internal tandem duplication mutation
    • Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT3 internal tandem duplication mutation. Blood 2013;121:4655-62.
    • (2013) Blood , vol.121 , pp. 4655-4662
    • Ravandi, F.1    Alattar, M.L.2    Grunwald, M.R.3    Rudek, M.A.4    Rajkhowa, T.5    Richie, M.A.6
  • 27
    • 27644557122 scopus 로고    scopus 로고
    • Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation
    • Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff M, Konopleva M. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 2005;19: 1977-84.
    • (2005) Leukemia , vol.19 , pp. 1977-1984
    • Zhang, W.1    McQueen, T.2    Schober, W.3    Rassidakis, G.4    Andreeff, M.5    Konopleva, M.6
  • 28
    • 84859627981 scopus 로고    scopus 로고
    • MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
    • Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012;26:778-87.
    • (2012) Leukemia , vol.26 , pp. 778-787
    • Konopleva, M.1    Milella, M.2    Ruvolo, P.3    Watts, J.C.4    Ricciardi, M.R.5    Korchin, B.6
  • 29
    • 77950212489 scopus 로고    scopus 로고
    • Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim
    • Zhang W, Konopleva M, Burks JK, Dywer KC, Schober WD, Yang JY, et al. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res 2010;70:2424-34.
    • (2010) Cancer Res , vol.70 , pp. 2424-2434
    • Zhang, W.1    Konopleva, M.2    Burks, J.K.3    Dywer, K.C.4    Schober, W.D.5    Yang, J.Y.6
  • 30
    • 9744254768 scopus 로고    scopus 로고
    • Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses
    • Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004;10:7994-8004.
    • (2004) Clin Cancer Res , vol.10 , pp. 7994-8004
    • Zhao, L.1    Wientjes, M.G.2    Au, J.L.3
  • 31
    • 84876491866 scopus 로고    scopus 로고
    • Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells
    • Gunawardane RN, Nepomuceno RR, Rooks AM, Hunt JP, Ricono JM, Belli B, et al. Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells. Mol Cancer Ther 2013;12:438-47.
    • (2013) Mol Cancer Ther , vol.12 , pp. 438-447
    • Gunawardane, R.N.1    Nepomuceno, R.R.2    Rooks, A.M.3    Hunt, J.P.4    Ricono, J.M.5    Belli, B.6
  • 32
    • 84878916655 scopus 로고    scopus 로고
    • The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD(+) AML but retains in vitro sensitivity to PKC412 and Sunitinib
    • Albers C, Leischner H, Verbeek M, Yu C, Illert AL, Peschel C, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD(+) AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia 2013;27:1416-8.
    • (2013) Leukemia , vol.27 , pp. 1416-1418
    • Albers, C.1    Leischner, H.2    Verbeek, M.3    Yu, C.4    Illert, A.L.5    Peschel, C.6
  • 33
    • 84865074356 scopus 로고    scopus 로고
    • Crenolanib inhibits the drug-resistantPDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors
    • Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A Ramachandran A, et al. Crenolanib inhibits the drug-resistantPDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012;18:4375-84.
    • (2012) Clin Cancer Res , vol.18 , pp. 4375-4384
    • Heinrich, M.C.1    Griffith, D.2    McKinley, A.3    Patterson, J.4    Presnell, A.5    Ramachandran, A.6
  • 34
    • 70449707509 scopus 로고    scopus 로고
    • Phase i study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers
    • Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 2009;27:5262-9.
    • (2009) J Clin Oncol , vol.27 , pp. 5262-5269
    • Lewis, N.L.1    Lewis, L.D.2    Eder, J.P.3    Reddy, N.J.4    Guo, F.5    Pierce, K.J.6
  • 35
    • 38049019119 scopus 로고    scopus 로고
    • Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials
    • Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-48.
    • (2008) Cancer Chemother Pharmacol , vol.61 , pp. 535-548
    • Takimoto, C.H.1    Awada, A.2
  • 36
    • 79953073247 scopus 로고    scopus 로고
    • FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
    • Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011;117:3286-93.
    • (2011) Blood , vol.117 , pp. 3286-3293
    • Sato, T.1    Yang, X.2    Knapper, S.3    White, P.4    Smith, B.D.5    Galkin, S.6
  • 37
    • 78649931161 scopus 로고    scopus 로고
    • Will newer tyrosine kinase inhibitors have an impact in AML?
    • Levis MJ. Will newer tyrosine kinase inhibitors have an impact in AML? Best Pract Res Clin Haematol 2010;23:489-94.
    • (2010) Best Pract Res Clin Haematol , vol.23 , pp. 489-494
    • Levis, M.J.1
  • 38
    • 84861906112 scopus 로고    scopus 로고
    • Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
    • Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012;119: 5133-43.
    • (2012) Blood , vol.119 , pp. 5133-5143
    • Man, C.H.1    Fung, T.K.2    Ho, C.3    Han, H.H.4    Chow, H.C.5    Ma, A.C.6
  • 39
    • 0036659931 scopus 로고    scopus 로고
    • Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    • Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
    • (2002) Blood , vol.100 , pp. 59-66
    • Schnittger, S.1    Schoch, C.2    Dugas, M.3    Kern, W.4    Staib, P.5    Wuchter, C.6
  • 40
    • 58149104523 scopus 로고    scopus 로고
    • Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: Effects on PKC412-sensitive and-resistant FLT3-expressing cells
    • Weisberg E, Roesel J, Bold G, Furet P, Jiang J, Cools J, et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and-resistant FLT3-expressing cells. Blood 2008;112:5161-70.
    • (2008) Blood , vol.112 , pp. 5161-5170
    • Weisberg, E.1    Roesel, J.2    Bold, G.3    Furet, P.4    Jiang, J.5    Cools, J.6
  • 41
    • 84867796218 scopus 로고    scopus 로고
    • Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia
    • Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 2012;120: 3069-79.
    • (2012) Blood , vol.120 , pp. 3069-3079
    • Williams, A.B.1    Li, L.2    Nguyen, B.3    Brown, P.4    Levis, M.5    Small, D.6
  • 42
    • 84888263107 scopus 로고    scopus 로고
    • Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
    • Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 2013;122:3607-15.
    • (2013) Blood , vol.122 , pp. 3607-3615
    • Zimmerman, E.I.1    Turner, D.C.2    Buaboonnam, J.3    Hu, S.4    Orwick, S.5    Roberts, M.S.6
  • 43
    • 84899738513 scopus 로고    scopus 로고
    • Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
    • Oct 8 [Epub ahead of print]
    • Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br JHaematol 2013 Oct 8[Epub ahead of print]
    • (2013) Br JHaematol
    • Yang, X.1    Sexauer, A.2    Levis, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.